Mainz Biomed NV

Insider buying surge at Mainz Biomed NV: CFO William Caragol’s zero‑cash purchase signals confidence in upcoming pancreatic‑cancer diagnostics and a new private placement, hinting at potential share‑price upside.

Insider buys in a quiet biopharma stock signal confidence in breakthrough pancreatic diagnostics and KRAS‑G12D therapy, but the market remains flat.

Explore how insider trades at Mainz Biomed NV signal potential dilution or strategic shifts, and learn key actions investors should take to assess future upside.